Hi all - I have been a shareholder on AHZ for a few years now. my first post on AHZ.
Headline news on the 4c - revenue up 47% - I read this and think wow - all is on track. Then thanks to one of the posts on this thread it is pointed out it is 47% up on March 14 quarter. - really - who cares- this is simply misleading. All we care about and the future of AHZ is the quarter on quarter CC sales growth. Not a mention the 47% growth was from a quarter 12 months ago
I believe AHZ will eventually be very successful. The product speaks for itself. It is up to managements to deliver how much value. I did not understand the timing of the fund raising, I am disappointed that no new major shareholders were introduced in the placement and now I feel I can no longer trust what management are saying and I need to check and double check what management are saying.
The question now being raised in my mind - is management hiding something
This is environment that DOES NOT invites a long term shareholding
- Forums
- ASX - By Stock
- AVR
- Quarterly
Quarterly, page-92
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 18.000 |
1 | 681 | 17.900 |
2 | 451 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
18.000 | 100 | 1 |
18.240 | 500 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online